Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Rises By 193.9%

The Oncology Institute, Inc. (NASDAQ:TOI) saw a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 1,240,000 shares, a growth of 193.9% from the November 15th total of 421,900 shares. Currently, 3.4% of the company’s shares are short sold. Based on an average daily trading volume, of 1,540,000 shares, the days-to-cover ratio is presently 0.8 days.

Oncology Institute Trading Down 3.1 %

Shares of NASDAQ TOI traded down $0.01 during trading on Friday, reaching $0.22. The company had a trading volume of 247,852 shares, compared to its average volume of 534,100. Oncology Institute has a 12 month low of $0.13 and a 12 month high of $2.50. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91. The stock has a market cap of $16.84 million, a P/E ratio of -0.29 and a beta of 0.43. The company’s fifty day moving average price is $0.26 and its 200-day moving average price is $0.36.

Insider Activity

In related news, Director Brad Hively acquired 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was acquired at an average cost of $0.17 per share, for a total transaction of $42,500.00. Following the completion of the acquisition, the director now directly owns 616,753 shares of the company’s stock, valued at approximately $104,848.01. This trade represents a 68.17 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 9.50% of the stock is currently owned by insiders.

Institutional Trading of Oncology Institute

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tiff Advisory Services LLC boosted its stake in shares of Oncology Institute by 235.1% in the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock valued at $653,000 after purchasing an additional 995,280 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Oncology Institute by 142.3% in the second quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock valued at $156,000 after buying an additional 199,300 shares during the period. Finally, HighTower Advisors LLC boosted its position in Oncology Institute by 190.8% during the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock valued at $27,000 after acquiring an additional 53,382 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.